Cytek Biosciences (CTKB) Return on Invested Capital (2023 - 2026)

Cytek Biosciences' Return on Invested Capital history runs 4 years deep, the most recent figure standing at 0.34% for Q1 2026.

• Quarterly Return on Invested Capital fell 27.0% year-over-year to 0.34% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.34% (down 27.0% YoY) and the FY2025 annual result came in at 1.14%, down 98.0% from the prior year.
• Return on Invested Capital was 0.34% for Q1 2026 at Cytek Biosciences, down from 0.29% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.02% in Q1 2023 and bottomed at 0.34% in Q1 2026.
• A 4-year average of 0.08% and a median of 0.04% in 2024 frame the typical range for Return on Invested Capital.
• Annual changes were most pronounced in 2024 — Return on Invested Capital changed 0 bps — and 2026, when it slipped 27 bps.
• Cytek Biosciences' Return on Invested Capital stood at 0.03% in 2023, then tumbled by 45 bps to 0.04% in 2024, then slumped by 605 bps to 0.29% in 2025, then retreated by 21 bps to 0.34% in 2026.
• Business Quant data shows CTKB's Return on Invested Capital at 0.34% in Q1 2026, 0.29% in Q4 2025, and 0.07% in Q3 2025.